ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

ЧӦÃæ·¨ÓÅ»¯¼×ÛÏßäßò¾ÛÈéËá_ҩѧ±ÏÒµÂÛÎÄ

·¢²¼Ê±¼ä£º2014-10-26 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
¡¾¹Ø¼ü´Ê¡¿ ÖصþµÈ¸ßÏßͼ ÕªÒª£ºÄ¿µÄ ÓÅ»¯¼×ÛÏßäßò¾ÛÈéËáôÇ»ùÒÒËá¹²¾ÛÎï΢ÇòµÄ´¦·½¹¤ÒÕ¡£·½·¨ ²ÉÓÃO/OÐÍÈ黯ÈܼÁ»Ó·¢·¨ÖƱ¸Î¢Çò£¬Í¨¹ýDraper/linСÖÐÐĸ´ºÏÒò×ÓÉè¼ÆÊÔÑ鿼²ìÒ©ÎïºÍPLGAµÄÖØÁ¿±È¡¢PLGAÔÚÄÚÏàµÄŨ¶È¡¢Ë¾ÅÌ-80ÔÚÍâÏàµÄŨ¶È3¸öÓ°ÏìÒò×Ó¶Ô΢ÇòµÄ°ü·âÂÊ¡¢ÔØÒ©Á¿ºÍÁ£¾¶µÄÓ°Ïì¡£¸ù¾Ý×î¼ÑÊýѧģÐÍ»æÖÆЧӦÃ棬ͨ¹ýÖصþµÈ¸ßÏßͼȷ¶¨×îÓÅ´¦·½¹¤ÒÕ¡£½á¹û 3¸öÓ°ÏìÒòËغÍ3¸ö¿¼²ìÖ¸±êÖ®¼ä´æÔÚ¶¨Á¿¹Øϵ£¬ÓÅ»¯´¦·½¹¤ÒÕΪҩÎïºÍPLGAµÄÖØÁ¿±ÈΪ0.08¡Ã1£¬PLGAµÄŨ¶ÈΪ40%£¬Ë¾Å̵ÄŨ¶ÈΪ5%¡£ÓÅ»¯´¦·½¸÷Ö¸±êµÄÔ¤²âÖµºÍÄ¿±êÖµ·Ç³£½Ó½ü¡£½áÂÛ ²ÉÓÃÒò×ÓÉè¼Æ-ЧӦÃæ·¨Íê³ÉÁ˼×ÛÏßäßò΢ÇòµÄ¶àÄ¿±êͬ²½ÓÅ»¯¡£ ¹Ø¼ü´Ê£º¼×ÛÏßäßò;΢Çò;O/OÐÍÈ黯ÈܼÁ»Ó·¢·¨;ЧӦÃæ·¨;ÖصþµÈ¸ßÏßͼ Abstract£º Objective To optimize the formulation of methimazoleloaded polylacticcoglycolic acid (PLGA) microspheres. Methods Methimazoleloaded PLGA microspheres were prepared by the oilinoil emulsion solvent evaporation technique. Three factors,including the weight ratio of drug to PLGA,PLGA concentration in internal phase and the emulsifier (Span 80) concentration in external phase,were known to be associated with the quality of the microspheres. A small composite design (Draper/Lin method) was used to investigate the effects of the three factors on encapsulation efficiency,drug loading and size distribution. Response surface and overlay contour plot were delineated according to the bestfit mathematic models. Optimum formulation was selected by overlay contour plot. Results The quantitative relationships between the three factors and three responses were obtained. The variables were optimized and the following processing conditions resulted in the highest drug loading and best yields of the microspheres£º the weight ratio of drug to PLGA was 0.08£º1,PLGA and Span 80 concentration was 40% and 5%,respectively. The predicted and observed values of the optimum formulation were in close agreement. Conclusion The multiobjective simultaneous optimization of the formulation of methimazoleloaded microspheres was obtained by response surface methodology. Key words£ºmethimazole; microspheres; oilinoil emulsion solvent evaporation; response surface methodology;overlay contour plot ÉúÎï¿É½µ½â¾ÛºÏÎï×¢Éä΢Çò˳ӦÁËÏÖ´úÒ©¼ÁѧÏò³¤Ð§¡¢¸ßЧºÍµÍ¶¾µÄ·¢Õ¹·½Ïò£¬½üÈýÊ®ÄêÀ´Ò»Ö±ÊÇÒ©¼ÁѧÑо¿µÄÈȵãÖ®Ò»¡£¾Ûõ¥Àà¸ß·Ö×Ó²ÄÁÏÈéËáôÇ»ùÒÒËá¹²¾ÛÎï(poly lacticcoglycolic acid,PLGA)ÔÚÌåÄÚ¿É×îÖÕ´úл³ÉË®ºÍ¶þÑõ»¯Ì¼£¬ÓÉÓÚÆäÁ¼ºÃµÄÉúÎï¿É½µ½âÐÔºÍÏàÈÝÐÔ¶ø±¸ÊÜÑо¿ÕßµÄÇàíù¡£¹ØÓÚPLGA΢ÇòÖƼÁµÄ±¨µÀÉæ¼°µ½¸÷ÖÖ²»Í¬Ò©Àí»îÐԵĻ¯ºÏÎïÈ翹°©ÀàÒ©Îï¡¢·ÇçÞÌ忹Ñ×Ò©Îï¡¢¿¹ÔçÀÏÐÔ³Õ´ôÒ©ÎïÒÔ¼°¶àëÄÀàÒ©Îï¡£´ÓÒ©ÎïµÄÈܽâÐÔÖʺͷÖ×ÓÁ¿À´¿´£¬ÖƳÉ΢ÇòÖƼÁµÄÒ©Îï¶àÊÇһЩˮÈÜÐÔ²îµÄС·Ö×ÓÒ©ÎïºÍË®ÈÜÐԵĶàëÄÀàÒ©Îï[1-3]£¬Ë®ÈÜÐÔС·Ö×ÓÒ©ÎïÓÉÓÚ²»ÈÝÒ×°ü·âºÍ¿ØÊÍЧ¹û²»ºÃ£¬Ïà¹ØµÄ±¨µÀ½ÏÉÙ¡£±¾¿ÎÌâÒÔÖÎÁƼ׿ºµÄË®ÈÜÐÔÒ©Îï¼×ÛÏßäßòΪģÐÍÒ©Î²ÉÓÃO/OÐÍÈ黯ÈܼÁ»Ó·¢·¨ÖƱ¸PLGA΢Çò£¬Í¨¹ý¸Ä½øµÄ²¿·ÖÒò×ÓÉè¼ÆºÍЧӦÃæ·¨ÓÅ»¯¹¤ÒÕ£¬ÒÔÆڵõ½°ü·âÂʺÍÔØÒ©Á¿½Ï¸ß¡¢Á£¾¶ÊÊÖеļ×ÛÏßäßò΢ÇòµÄÖƱ¸¹¤Òպʹ¦·½¡£ 1 ²ÄÁÏÓëÒÇÆ÷ ¼×ÛÏßäßò(½­ËÕ½ð̳ÊÐÕýµ¤»¯¹¤³§£¬050602)£¬PLGA(LA/GAΪ75¡Ã25£¬·Ö×ÓÁ¿15 000£¬É½¶«Ò½ÁÆÆ÷еÑо¿Ëù)£¬¶þÂȼ×Íé¡¢ÒºÌåʯÀ¯¡¢ÒÒ¾¦¡¢Õý¼ºÍé(·ÖÎö´¿)£¬Ë¾ÅÌ-80(Ìì½òÊйã³É»¯Ñ§ÊÔ¼ÁÓÐÏÞ¹«Ë¾);ÊýÏÔʽµç¶¯½Á°èÆ÷(ÉϺ£Ë¾ÀÖÒÇÆ÷ÓÐÏÞ¹«Ë¾);UV¨D260ÐÍ×ÏÍâ·Ö¹â¹â¶È¼Æ(ÈÕ±¾µº½ò);¹âѧÏÔ΢¾µ(OLYMPUS BX¨D50)¡£ 2 ·½ ·¨ 2.1 ¼×ÛÏßäßò΢ÇòµÄÖƱ¸ °´ÕÕÒ»¶¨±ÈÀý³ÆÈ¡¼×ÛÏßäßòºÍPLGAÊÊÁ¿£¬ÈÜÓÚ1 mlÒÒëæ¶þÂȼ×Íé(Ìå»ý±È2¡Ã3)µÄ»ìºÏÈܼÁÖУ¬µÎÈë10 mLÒ»¶¨Å¨¶ÈµÄ˾ÅÌ-80ÈÜÒºÖУ¬500 r/minÈ黯£¬½Á°è4 hºó£¬³Á½µ£¬ÓÃÕý¼ºÍéÏ´µÓ΢Çò£¬Õæ¿Õ¸ÉÔï24 hºó£¬¼´µÃ¡£ 2.2 ¼×ÛÏßäßò΢ÇòµÄÔØÒ©Á¿ºÍ°ü·âÂʵIJⶨ ¾«ÃܳÆÈ¡¼×ÛÏßäßò΢Çò15 mgÓÚ10 mLÀëÐĹÜÖУ¬¼ÓÈë¶þÂȼ×Íé1 mL£¬äöÎÐÕñµ´2 minÖÁ΢ÇòÍêÈ«Èܽ⣬¼ÓÈëË®ÈÜÒº5 mL£¬äöÎÐÕñµ´2 min£¬2 500 r/minÀëÐÄ15 min £¬È¡ÉÏÇåÒº0.2 mLÖÃÓÚ10 mLÈÝÁ¿Æ¿ÖУ¬ÓÃË®ÈÜÒº¶¨ÈÝ£¬µÃµ½¹©ÊÔÈÜÒºA¡£ÅäÖÆŨ¶ÈԼΪ1 mg・ml-1¼×ÛÏßäßòµÄ¶þÂȼ×ÍéÈÜÒº£¬¾«ÃÜÁ¿È¡1 mLÖÃÓÚ10 mLÀëÐĹÜÖУ¬Í¬·¨²Ù×÷£¬µÃµ½¶ÔÕÕÈÜÒºB¡£252 nm²â¶¨ÎüÊնȣ¬Í¨¹ýÈÜÒºAºÍÈÜÒºBµÄÎüÊնȱÈÖµ£¬¼ÆËã΢ÇòµÄÔØÒ©Á¿¡£°ü·âÂÊΪʵ¼ÊÔØÒ©Á¿ºÍÀíÂÛÔØÒ©Á¿µÄ±ÈÖµ¡£ 2.3 ΢ÇòÁ£¾¶µÄ²â¶¨ ²ÉÓùâѧÏÔ΢¾µ¹Û²ì΢ÇòµÄÍâ¹ÛÐÎ̬£¬²â¶¨²»ÉÙÓÚ200¸ö΢ÇòµÄÁ£¾¶£¬¼ÆËãËãÊõƽ¾ùÁ£¾¶¡£ 2.4 ¼×ÛÏßäßò΢ÇòÖƱ¸¹¤Òպʹ¦·½µÄÓÅ»¯ ÔÚһϵÁÐԤʾÊÔÑéµÄ»ù´¡ÉÏ£¬¹Ì¶¨Ä³Ð©ÒòËصÄˮƽÈçÄÚÏàµÄÈܼÁ×é³É¡¢ÍâÏàºÍÄÚÏàµÄÌå»ý±È¡¢½Á°èËٶȵȣ¬²ÉÓÃSASͳ¼ÆѧÈí¼þADXÄ£¿éËùÌṩµÄDraper/Lin·½·¨Éè¼ÆÊÔÑ飬¶ÔÒ©ÎïºÍPLGAµÄÖØÁ¿±È¼´ÀíÂÛÔØÒ©Á¿(X1)¡¢PLGAÔÚÄÚÏàµÄŨ¶È(X2)¡¢Ë¾ÅÌ-80ÔÚÍâÏàµÄŨ¶È(X3)3Òò×Ó½øÐÐÓÅ»¯¡£¿¼²ìÖ¸±ê(Y)Ϊ΢ÇòµÄ°ü·âÂÊ(Y1)¡¢ÔØÒ©Á¿(Y2)ºÍÁ£¾¶(Y3)¡£¸÷ÒòËØˮƽµÄÉèÖüû±í1£¬ÊÔÑé°²Åż°½á¹û¼û±í2¡£±í1 Òò×Ó¼°Ë®Æ½(ÂÔ)±í2 Draper/LinÉè¼ÆµÄÊÔÑé°²Åż°½á¹û(ÂÔ) ЧӦÃæ·¨ÓÅ»¯¼×ÛÏßäßò¾ÛÈéËáôÇ»ùÒÒËá¹²¾ÛÎï΢ÇòµÄ´¦·½¹¤ÒÕDraper/LinÉè¼Æ£¬ÓÖ³ÆΪСÖÐÐĸ´ºÏÉè¼Æ(small center composite design)£¬ÓеÄÎÄÏ×±¨µÀ³ÆBoxwilsonÉè¼ÆÊÇÒ»ÖָĽøµÄ²¿·ÖÒò×ÓÉè¼Æ[4]¡£ËüµÄÉè¼Æ±íÓÉÁ½²¿·Ö×é³É£¬Éϲ¿·ÖÊÇÒ»¸ö¶þˮƽµÄ²¿·ÖÒò×ÓÉè¼Æ±í;Ï°벿·Ö°üÀ¨5¸öÖÐÐĶÔÕÕµãÒÔ¼°Ò»×éÒÔÒò×ÓÊýΪ¿Õ¼äάÊý£¬ÔÚ×ø±êÉϹØÓÚÔ­µã¶Ô³ÆµÄµã(¼û±í2)¡£±í1ÖÐ-1.414,-1,0,1,1.414·Ö±ð´ú±í5¸öˮƽ£¬ÕâÖÖ·½Ê½³ÆΪ´úÂëÐÎʽ£¬×îºóµÄÊý¾Ý´¦ÀíÒ²¿ÉÒÔÓÃÕâЩ´úÂëÀ´½øÐС£½«ÓÅ»¯ºóµÄ½á¹û´úÂë»»Ëã³ÉʵÑéÊýÖµ¾Í¿ÉÒԵõ½ËùÐèµÄÓÅ»¯ºóµÄ¹¤ÒÕ²ÎÊý¡£ ²ÉÓÃSASͳ¼ÆѧÈí¼þͨ¹ýÒÔÏÂÄ£ÐͶÔÊÔÑéÊý¾Ý½øÐзÇÏßÐÔÄâºÏ£¬ÒÔÄ£Ð͵ÄR2ºÍF¼ìÑé½á¹û£¬ÒÔ¼°¸÷ÒòËصÄt¼ìÑé½á¹û×÷ΪģÐÍÄâºÏµÄÅж¨±ê×¼¡£ Y=b0+b1X1+b2X2+b3X3+b12X1X2+b23X2X3+ b13X1X3+b11X22+b22X22+b33X23 Y±íʾ¿¼²ìÖ¸±ê£¬X1¡«X3´ú±íÓ°ÏìÒò×Ó£¬b0´ú±í½Ø¾àÏb´ú±í¸÷Ó°ÏìÒò×ÓµÄϵÊý¡£ 3 ½á ¹û 3.1 ¼×ÛÏßäßò΢Çòº¬Á¿²â¶¨µÄ·½·¨Ñ§¿¼²ì ÔÚ¦Ñ=1¡«6 ¦Ìg・mL-1·¶Î§ÄÚ¼×ÛÏßäßòË®ÈÜÒºÔÚ252 nm´¦AÓë¦ÑÓÐÁ¼ºÃµÄÏßÐÔ¹Øϵ¡£¼×ÛÏßäßò΢Çò²ÉÓöþÂȼ×ÍéÈܽ⣬ÓÃË®ÌáÈ¡ºó×ÏÍâ¼ì²âµÄ·½·¨²â¶¨º¬Á¿¡£¿Õ°×΢ÇòÔڲⶨ²¨³¤ÎÞ×ÏÍâÎüÊÕ£¬¸Ã²â¶¨·½·¨ÔÚµÍ(2 ¦Ìg・mL-1)¡¢ÖÐ(4 ¦Ìg・mL-1)¡¢¸ß(6 ¦Ìg・mL-1)Ũ¶ÈµÄƽ¾ù»ØÊÕÂÊΪ(100.56¡À0.52)%¡£ 3.2 Draper/LinÉè¼ÆÊÔÑé½á¹û 15Åú΢Çò°ü·âÂÊ¡¢ÔØÒ©Á¿ºÍÁ£¾¶µÄ¼ì²â½á¹û¼û±í2£¬ÊÔÑéÊý¾ÝµÄÄ£ÐÍÄâºÏ½á¹û¼û±í3¡£¸ù¾ÝÄâºÏ·½³Ì½«´ÎÒªµÄÒòËع̶¨ÔÚijһˮƽ£¬»æÖÆÓ°ÏìÒòËغ͸÷¿¼²ìÖ¸±êÏìÓ¦ÖµµÄÈýάͼ¼ûͼ1¡«3¡£±í3 Ä£ÐÍÄâºÏµÄ½á¹û(ÂÔ) 3.2.1 Ó°Ïì°ü·âÂʵÄÖ÷ÒªÒòËØ ´Ó±í3ºÍͼ1¿ÉÒÔ¿´³öÓ°Ïì°ü·âÂʵÄÖ÷ÒªÒòËØÊÇPLGAµÄŨ¶È¡¢Ò©ÎïºÍÔØÌåµÄ±ÈÀý(ÀíÂÛÔØÒ©Á¿)£¬ÆäÖÐÇ°ÕßµÄÓ°Ïì¸ü´ó£¬Ëæ×ÅPLGAŨ¶ÈµÄÔö¼Ó£¬Î¢ÇòµÄ°ü·âÂÊ×î¶à¿ÉÔö¼Ó½ü40%¡£ 3.2.2 Ó°ÏìÔØÒ©Á¿µÄÖ÷ÒªÒòËØ PLGAµÄŨ¶ÈºÍÀíÂÛÔØÒ©Á¿¶¼»áÏÔÖøµÄÓ°Ïì΢ÇòµÄÔØÒ©Á¿£¬ÆäÖÐÀíÂÛÔØÒ©Á¿µÄÓ°ÏìÁ¦¸üÇ¿¡£µ«ÊÇÔö¼ÓÒ©ÎïºÍÔØÌåÖÊÁ¿±ÈÔÚÌá¸ß΢Çòʵ¼ÊÔØÒ©Á¿µÄͬʱ£¬°ü·âÂÊ»áÓÐËù½µµÍ¡£ 3.2.3 Ó°Ïì΢ÇòÁ£¾¶µÄÖ÷ÒªÒòËØ PLGAµÄŨ¶ÈºÍ˾Å̵ÄŨ¶È¶¼»áÓ°Ïì΢ÇòµÄÁ£¾¶£¬ÆäÖÐ˾Å̵ÄÓ°Ïì¸ü´ó¡£´Óͼ3 ¿ÉÒÔ¿´³öËæ×ÅÁ½ÕßÓëÁ£¾¶³ÊÏÖ³öÃ÷ÏԵķÇÏßÐÔµÄÏà¹ØÐÔ¡£µ±X3¡Ö0.5,X2¡Ö-0.5£¬Î¢ÇòµÄÁ£¾¶×îС¡£µ±Ë¾Å̵ÄŨ¶È´¦Ôڽϵ͵Äˮƽʱ(ÈçX30.5)£¬Ëæ×Å˾ÅÌŨ¶ÈµÄÔö¼Ó£¬ÓÉÓÚÈ黯ÄÜÁ¦Ôö¼Ó£¬Î¢ÇòµÄÁ£¾¶½µµÍ¡£µ±Ë¾Å̵ÄŨ¶È´¦ÔڽϸߵÄˮƽ(ÈçX30.5)£¬Ëæ×Å˾ÅÌŨ¶ÈµÄÔö¼Ó£¬Î¢ÇòµÄÁ£¾¶ÓÐÔö¼ÓµÄÇ÷ÊÆ£¬ÕâÊÇÒòΪÔö¼Ó˾Å̵ÄŨ¶È»áÔÚÒ»¶¨³Ì¶ÈÉÏÔö¼ÓÌåϵµÄð¤¶È£¬È黯ËùÐèÒªµÄ¼ôÇÐÁ¦Ôö´ó¡£PLGAŨ¶È¶ÔÁ£¾¶µÄÓ°ÏìÒ²ÓëPLGAËù´¦µÄˮƽÓйء£µ±PLGAŨ¶È½ÏµÍʱ£¬Å¨¶È¶ÔÁ£¾¶µÄÓ°Ïì½ÏС;µ±PLGAµÄŨ¶È½Ï¸ßʱ£¬Ëæ×ÅPLGAŨ¶ÈµÄÔö¼Ó£¬Î¢ÇòµÄÁ£¾¶Ôö¼Ó¡£ÕâÖ÷ÒªÓÐÁ½·½ÃæÔ­ÒòÊ×ÏÈÊÇËæ×ÅPLGAŨ¶ÈµÄÔö¼ÓÈÜÒºµÄð¤¶ÈÔö¼Ó£¬È黯ËùÐèµÄ¼ôÇÐÁ¦Ôö¼Ó£¬Æä´ÎÊÇËæ×ÅPLGAŨ¶ÈµÄÔö¼Ó£¬Î¢ÇòµÄ¹Ì»¯Ê±¼ä¼Ó¿ì£¬ÈéµÎÀ´²»¼°·ÖÉ¢³É¸üСµÄ΢Á£¡£ 3.3 ´¦·½ÓÅ»¯ ÀíÏëµÄ¼×ÛÏßäßò΢ÇòÔÚ¾ßÓнϸ߰ü·âÂʵÄͬʱ£¬Ò²Ó¦¾ßÓнϸߵÄÔØÒ©Á¿£¬´ËÍâΪÁ˱£Ö¤Î¢Çò¾ßÓÐÁ¼ºÃµÄͨÕëÐÔÁ£¾¶Ò²²»Ó¦Ì«´ó¡£½áºÏÊÔÑé½á¹ûÈ·¶¨ÁËÓÅ»¯Ö¸±êµÄÄ¿±êֵΪ£º°ü·âÂʲ»µÍÓÚ80%£¬ÔØÒ©Á¿Îª5%¡«10%£¬Æ½¾ùÁ£¾¶ÔÚ45¡«55 ¦Ìm·¶Î§ÄÚ¡£½«X3µÄˮƽ¹Ì¶¨ÔÚ0£¬¼´Ë¾ÅÌÔÚÍâÏàµÄŨ¶ÈΪ5%£¬»æÖÆÒòËØX1ºÍX2¶ÔÖ¸±êY1~Y3µÄÖصþµÈ¸ßÏßͼ£¬µÃµ½ÁËÄÜͬʱÂú×ãÉÏÊöÌõ¼þµÄÓÅ»¯ÇøÓò(¼ûͼ4)¡£´ÓÓÅ»¯ÇøÓòÖÐÑ¡¶¨X1ºÍX2µÄˮƽ·Ö±ðΪ-0.57ºÍ0.47£¬¼´ÓÅ»¯´¦·½¹¤ÒÕΪҩÎïºÍPLGAµÄÖØÁ¿±ÈΪ0.08¡Ã1£¬PLGAµÄŨ¶ÈΪ40%£¬Ë¾Å̵ÄŨ¶ÈΪ5%¡£±í4 ÓÅ»¯´¦·½µÄÔ¤²âÖµºÍʵ²âÖµ(ÂÔ) ¸ù¾ÝÓÅ»¯µÄ´¦·½¹¤ÒÕÖƱ¸¼×ÛÏßäßò΢Çò£¬²¢²â¶¨°ü·âÂÊ¡¢ÔØÒ©Á¿ºÍÁ£¾¶£¬½á¹ûÏÔʾʵ²âÖµºÍÔ¤²âÖµ·Ç³£½Ó½ü£¬²ÉÓÃЧӦÃæ·¨¶àÄ¿±êͬ²½ÓÅ»¯¼×ÛÏßäßò΢ÇòµÄ´¦·½¹¤ÒÕ´ïµ½ÁËÔ¤ÆÚµÄЧ¹û¡£ 4 ÌÖ ÂÛ 4.1 È黯ÈܼÁ»Ó·¢·¨°üÀ¨Á½¸ö×î»ù±¾µÄ¹ý³Ì¼´È黯ºÍÈܼÁ»Ó·¢¹ý³Ì£¬Ó°ÏìÈܼÁ»Ó·¢ËٶȺͳ̶ȵÄÒòËØÈçÈ黯¼ÁµÄÓÃÁ¿¡¢ÔØÌåµÄŨ¶È¡¢ÄÚÍâÏàµÄÌå»ýµÈ¶¼»áÓ°Ï쵽΢ÇòµÄÐÔÖÊ(ÐÎ̬¡¢Á£¾¶¡¢ÔØÒ©Á¿¡¢°ü·âÂʺÍÊÍÒ©ÇúÏß)¡£¶øÕâЩÒòËصÄÓ°Ïì×÷ÓÃÊǸ´Ôӵģ¬²»ÊǼòµ¥µÄÏßÐÔ¹Øϵ£¬¸÷ÒòËØËù´¦µÄˮƽֱ½Ó¹Øϵµ½Æä¶Ô¿¼²ìÖ¸±êÓ°ÏìµÄ·½Ê½ºÍ´óС£¬Òò´ËÔÚ´¦·½¹¤ÒÕÓÅ»¯Ê±ÎÒÃÇÐèҪѡÔñÒ»ÖÖ¶àˮƽµÄʵÑéÉè¼ÆDraper/LinÉè¼Æ¡£ÕâÖָĽøµÄ²¿·ÖÒò×ÓÉè¼Æ·¨¿¼²ìµÄˮƽÊý¶à£¬ÊÔÑé´ÎÊýÉÙ£¬±ÈÕý½»Éè¼ÆºÍ¾ùÔÈÉè¼Æ¸ü¿ÆѧºÍ¿É¿¿¡£ 4.2 ΢ÇòµÄ´¦·½¹¤ÒÕ³£Éæ¼°µ½¶àÖ¸±êͬ²½ÓÅ»¯µÄÎÊÌ⣬¹ýÈ¥¶à²ÉÓÃ×ÛºÏÆÀ·Ö·¨´¦Àí£¬ÕâÖÖ·½·¨±È½Ï´Ö²Ú¶øÇÒÖ÷¹ÛÐÔ½ÏÇ¿£¬Ä¿Ç°±È½Ï¿ÆѧºÍÏȽøµÄÓÅ»¯·½·¨ÊǸù¾ÝЧӦÇúÏßµÄͼÏñ½øÐÐÅбð[5£¬6]¡£±¾ÎÄͨ¹ýÖÐÐĸ´ºÏÉè¼ÆЧӦÃæ·¨½¨Á¢ÁËÈý¸öÓ°ÏìÒòËØ(Ò©ÎïºÍPLGAµÄÖØÁ¿±È¡¢PLGAÔÚÄÚÏàµÄŨ¶È¡¢Ë¾ÅÌÔÚÍâÏàµÄŨ¶È)ÓëÈý¸ö¿¼²ìÖ¸±êÏìÓ¦Öµ(°ü·âÂÊ¡¢ÔØÒ©Á¿ºÍÁ£¾¶)µÄÊýѧģÐÍ£¬²ÉÓÃÖصþµÈ¸ßÏß·¨ÊµÏÖÁË΢ÇòµÄ¶àÖ¸±êÓÅ»¯£¬ÕâÖÖÓÅ»¯µÄ·½·¨ÖµµÃÔÚÐÂÐ͸øҩϵͳµÄ¹¤ÒÕɸѡÑо¿ÖнøÒ»²½Íƹ㡣 ²Î¿¼ÎÄÏ×£º [1]KYO M,HYON S H,IKADA Y. Effects of preparation conditions of cisplatinloaded microspheres on the in vitro release[J].J Control Release,1995,35£º73. [2]YANG Y Y,CHUNG T S. Morphology,drug distribution,and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by doubleemulsion solvent extraction /evaporation method[J].Biomaterials,2001,22 (3)£º 231. [3]HAN K,LEE K D,GAO Z G,et al. Preparation and evaluation of poly (Llactic acid)microspheres containin rhEGF for chronic gastric ulcer healing [J]. J of Controlled Release,2001,75 (3)£º259. [4]ƽÆäÄÜ.ÏÖ´úÒ©¼Áѧ[M].±±¾©£ºÖйúÒ½Ò©ÎÀÉú³ö°æÉ磬2000£º212 [5]½±ø£¬Ðì¹ú½Ü£¬ÕÅÈ껪.ÄÉÇúֲͪÈë¼ÁÌåÍâ´¦·½ÓÅ»¯[J].ÖйúҩѧÔÓÖ¾£¬2000£¬35(7)£º452 [6]ÎâÌΣ¬ÅËÎÀÈý£¬³Â¼ÃÃñ£¬µÈ.¶àÄ¿±êͬ²½ÓÅ»¯ÁòËáɳ¶¡°·´¼Éø͸±Ã¿ØÊÍƬµÄÖƱ¸¹¤ÒÕ[J].ҩѧѧ±¨£¬2002£¬35(8)£º617.
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö